Published Studies Related to Urocit-K (Potassium Citrate)
Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi. [2011.08.21]
In this article, we investigated the effect of the combined use of tamsulosin and potassium citrate (Uralyt-U((R))) for the treatment of uric acid stones in the distal ureter. The study was designed as a prospective, double blind randomized controlled trial... In conclusion, the use of urinary alkalization with tamsulosin can increase the frequency of spontaneous passage of distal ureteral uric acid stones especially those of 8-11 mm.
Prospective randomized clinical trial comparing phytotherapy with potassium citrate in management of minimal burden (</=8 mm) nephrolithiasis. [2011.05]
AIM: To compare efficacy and tolerability of phytotherapy (PT) vs. potassium citrate (KC) in patients with minimal nephrolithiasis. To compare and assess changes in value of certain serum (Ca(2)+, PO(4) (3-), uric acid [UA]) and urinary (24-hr Ca(2+), PO(4) (3-), UA, citrate, oxalate, and urine pH) parameters in patients being treated with PT or KC... CONCLUSIONS: Medical therapies with both KC and PT (with lupeol extract using Calcury) were effective in reducing the stone size and symptoms of nephrolithiasis. It appeared that KC was biochemically efficacious in producing some favorable biochemical changes with some side effects, whereas PT was probably clinically efficacious in hastening stone expulsion (<8 mm) without any observed adverse events. Although both the medical therapies were not effective in all aspects, we believe that PT using lupeol-based extract (Calcury) may be used as an alternative form of medical therapy in select patients with minimal nephrolithiasis. Long-term randomized placebo-controlled trials are needed to better define the precise role of lupeol-based PT vs. citrate therapy in minimal nephrolithiasis.
Splenda® improves tolerance of oral potassium citrate supplementation for
prevention of stone formation: results of a randomized double-blind trial. 
improves palatability without changing 24-hour urine parameters... CONCLUSION: Splenda significantly improves the palatability of KCit therapy and
Increased potassium intake from fruit and vegetables or supplements does not lower blood pressure or improve vascular function in UK men and women with early hypertension: a randomised controlled trial. [2010.12]
K-rich fruit and vegetables may lower blood pressure (BP) and improve vascular function. A randomised controlled trial (ISRCTN50011192) with a cross-over design was conducted in free-living participants with early stages of hypertension (diastolic BP>80 and < 100 mmHg, not receiving BP-lowering medication) to test this hypothesis...
Therapeutic effects of potassium sodium hydrogen citrate on melamine-induced urinary calculi in China. [2010.05.05]
BACKGROUND: In 2008, a sharp increase of the number of children diagnosed with urinary calculi was observed in China, 9433 children were diagnosed as having melamine-induced urinary calculi at outpatient clinic in Beijing Children's Hospital. This study examined the therapeutic efficacy of potassium sodium hydrogen citrate (PSHC) used to treat melamine-induced urinary stones in Chinese children who consumed melamine-containing infant formula... CONCLUSIONS: PSHC can significantly increase the successful expulsion rate and time of melamine-induced urinary calculi. The therapeutic efficacy is affected by PSHC dose, treatment duration, calculi position, and urinary pH. There is no relationship between the therapeutic efficacy and the stone size or patient age.
Clinical Trials Related to Urocit-K (Potassium Citrate)
Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones [Completed]
High amounts of calcium in the urine (hypercalciuria) can cause development of kidney stones
in children. Treatment for these children includes plenty of fluids, a low-salt diet and
medications such as potassium citrate. A major advantage of potassium citrate, as compared to
hydrochlorothiazide, is its lack of side effects. One problem the researchers and others
have observed is that some children continue to form kidney stones despite correction of
hypercalciuria with potassium citrate. One possible explanation is that in some individuals
potassium citrate therapy results in an excessive elevation of urine pH, a situation that may
predispose to calcium phosphate stone formation. In this study, the researchers will study
the effects of potassium citrate on urine chemistries and acid-base balance in three groups
of children aged 5-17 years:
- children who are hypercalciuric stone formers;
- healthy children without a history of hypercalciuria or kidney stones.
Particular attention will be paid to try to identify those who develop a very high urine pH
(>8) and the factors leading to this metabolic reaction.
The researchers will try to learn whether it is the child’s characteristics, the disease
manifestations, the dose of the drug, or a combination of the above which may be the cause of
the development of very alkaline urine. Based on the results, the researchers hope to be able
to better “tailor” the individual treatment for each child with kidney stones.
Effect of Neutralization of Endogenous Acid Production on Bone Mineral Density and Microarchitectural Composition of Bone [Recruiting]
Hypothesis: Neutralization of acid production induced by the Western diet with oral
administration of potassium citrate increases bone mineral density and bone mass as well as
skeletal muscle mass and strength in elderly people (> 65y).
Potassium Citrate to Prevent Age Related Bone Loss [Recruiting]
Osteoporosis, a disease in which the bones become weak and are more likely to break, is a
major health problem in the United States. Too much acid in the body appears to be linked to
loss of calcium via urine, bone loss, and muscle breakdown. The purpose of this study is to
determine the effect of various doses of potassium citrate, a supplement that can neutralize
acid, on bone density and muscle mass in older, healthy adults.
Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria [Completed]
OBJECTIVES: I. Evaluate the ability of a slow-releasing formulation of neutral potassium
phosphate to correct hypercalciuria and prevent recurrent stone formation in patients with
II. Evaluate the safety of this treatment. III. Compare the efficacy of potassium phosphate
to that of potassium citrate.
Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature [Not yet recruiting]